Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

@article{Burke2007AssessmentOR,
  title={Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.},
  author={Megan Elizabeth Burke and James R. Anderson and Simon Kao and David R Rodeberg and Stephen J. Qualman and Suzanne L Wolden and William Meyer and Philip P. Breitfeld},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 31},
  pages={
          4909-13
        }
}
PURPOSE Initial response to induction chemotherapy predicts failure-free survival (FFS) in osteosarcoma and Ewing's sarcoma. For Intergroup Rhabdomyosarcoma Study (IRS) IV patients with group III rhabdomyosarcoma, we assessed whether reported response assessed by anatomic imaging at week 8 predicted FFS. PATIENTS AND METHODS We studied 444 group III patients who received induction therapy, had response assessed at week 8 by anatomic imaging, and continued with protocol therapy. Induction… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Similar Papers

Loading similar papers…